Amylyx Pharmaceuticals (AMLX) Profit After Tax (2021 - 2026)

Amylyx Pharmaceuticals' Profit After Tax history runs 6 years deep, the most recent figure standing at -$41.3 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 14.97% year-over-year to -$41.3 million in Q1 2026; TTM through Mar 2026 was -$150.1 million, a 31.41% increase from a year earlier, with the FY2025 full-year figure at -$144.7 million, up 52.03% from the prior year.
• Profit After Tax fell to -$41.3 million in Q1 2026 per AMLX's latest filing, from -$33.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at $22.1 million in Q2 2023 and bottomed at -$118.8 million in Q1 2024.
• The 5-year median for Profit After Tax is -$41.3 million (2026), against an average of -$37.5 million.
• Across the five-year window, Profit After Tax jumped 140.83% in 2023 and plunged 7652.0% in 2024, its largest moves.
• Year by year, Profit After Tax stood at -$42.7 million in 2022, then jumped by 111.08% to $4.7 million in 2023, then slumped by 893.62% to -$37.5 million in 2024, then rose by 12.11% to -$33.0 million in 2025, then retreated by 25.11% to -$41.3 million in 2026.
• Per Business Quant, the three latest AMLX Profit After Tax figures stand at -$41.3 million (Q1 2026), -$33.0 million (Q4 2025), and -$34.4 million (Q3 2025).